Castle Biosciences has announced (pdf) it raised $11.8 million in financing.
Castle Biosciences, headquartered in Friendswood, Texas, is a cancer-focused molecular diagnostics company which currently offers prognostic tests for patients with cancers including uveal and cutaneous melanoma, esophageal, thymoma and brain cancers as well as malignant pleural mesothelioma.
The financing round was led by new investor HealthQuest Capital. Participation also included current Castle Biosciences' investors Mountain Group Capital and Affiliates, Longfellow Venture Partners and others.
Castle Biosciences indicated the funds would be used to expand clinical availability of its portfolio cancer diagnostic tests, including DecisionDx-Melanoma, its test to determine metastatic risk in patients with melanoma.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
